| Symbol | BGMS |
|---|---|
| Name | CYCLACEL PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 200 CONNELL DRIVE,SUITE 1500, BERKELEY HEIGHTS, New Jersey, 07922, United States |
| Telephone | +1 908 517-7330 |
| Fax | — |
| — | |
| Website | https://cyclacel.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001130166 |
| Description | Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom. Additional info from NASDAQ: |
(99% Neutral) CYCLACEL PHARMACEUTICALS, INC. (BGMS) Provides Business Update
Read more(99% Neutral) CYCLACEL PHARMACEUTICALS, INC. (BGMS) Announces Regulatory Update
Read more(99% Neutral) CYCLACEL PHARMACEUTICALS, INC. (BGMS) Announces Business Combination
Read moreBGMS Stock Alert: Halper Sadeh LLC is Investigating Whether Bio Green Med Solution, Inc. is Obtaining a Fair Price for its Shareholders
Read moreBIO GREEN MED SOLUTION, INC. ANNOUNCES BUSINESS COMBINATION AGREEMENT TO ACQUIRE FUTURE NRG SDN. BHD.
Read moreNew Form 425 - Bio Green Med Solution, Inc. <b>Filed:</b> 2026-06-04 <b>AccNo:</b> 0001493152-26-027294 <b>Size:</b> 621 KB
Read moreBIO GREEN MED SOLUTION REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read moreNew Form SCHEDULE 13G/A - Bio Green Med Solution, Inc. <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0001493152-26-022554 <b>Size:</b> 7 KB
Read moreNew Form DEFR14A - Bio Green Med Solution, Inc. <b>Filed:</b> 2026-05-01 <b>AccNo:</b> 0001493152-26-020898 <b>Size:</b> 3 MB
Read more(99% Neutral) CYCLACEL PHARMACEUTICALS, INC. (BGMS) Provides Business Update
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05817890 | Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects | Early_Phase1 | Healthy | Completed | 2023-03-03 | 2024-05-22 | ClinicalTrials.gov |
| NCT05358379 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymph… | Phase1 | Solid Tumor, Adult Lymphoma | Unknown | 2022-04-14 | 2025-11-01 | ClinicalTrials.gov |
| NCT05168904 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelo… | Phase1 | Leukemia | Suspended | 2021-10-22 | 2024-12-01 | ClinicalTrials.gov |
| NCT04983810 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tu… | Phase1 | Solid Tumor, Adult | Unknown | 2021-07-12 | 2025-06-30 | ClinicalTrials.gov |
| NCT04017546 | CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS | Phase1 | AML | Completed | 2019-08-02 | 2023-04-05 | ClinicalTrials.gov |
| NCT03884829 | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | Phase1 | AML, Adult | Terminated | 2019-03-25 | 2023-10-19 | ClinicalTrials.gov |
| NCT03739554 | CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL | Phase1 | Relapsed or Refractory Chronic Lymphocytic Leukemia | Completed | 2019-01-25 | 2023-04-27 | ClinicalTrials.gov |
| NCT03641755 | Olaparib + Sapacitabine in BRCA Mutant Breast Cancer | Phase1 | Breast Cancer | Active_Not_Recruiting | 2018-10-01 | 2026-10-22 | ClinicalTrials.gov |
| NCT02649751 | Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibros… | Phase2 | Cystic Fibrosis | Terminated | 2016-02-22 | 2018-07-26 | ClinicalTrials.gov |
| NCT02552953 | A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patien… | Phase1 | Cancer | Completed | 2015-09-28 | 2023-08-25 | ClinicalTrials.gov |
| NCT01303796 | A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Mye… | Phase3 | Acute Myeloid Leukemia | Completed | 2011-10-01 | 2017-07-31 | ClinicalTrials.gov |
| NCT01253460 | Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leuk… | Phase2 | Leukemia | Terminated | 2011-08-22 | 2019-02-13 | ClinicalTrials.gov |
| NCT01211457 | Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndro… | Phase1 | Acute Myeloid Leukemia | Unknown | 2010-06-17 | 2020-12-31 | ClinicalTrials.gov |
| NCT00999401 | A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Soli… | Phase1 | Advanced Solid Tumors | Completed | 2009-04-01 | 2019-08-13 | ClinicalTrials.gov |
| NCT00885963 | A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell… | Phase2 | Non-small Cell Lung Cancer | Terminated | 2008-12-01 | 2013-12-23 | ClinicalTrials.gov |
| NCT00590187 | Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly … | Phase2 | Acute Myeloid Leukemia | Completed | 2007-12-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT00560716 | A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Pa… | Phase1 | Solid Tumors | Terminated | 2007-06-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00476554 | A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cuta… | Phase2 | Cutaneous T-cell Lymphoma (CTCL) | Terminated | 2007-04-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00372073 | Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer | Phase2 | Non-small Cell Lung Cancer | Terminated | 2006-08-09 | 2009-04-07 | ClinicalTrials.gov |
| NCT00380653 | Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or My… | Phase1 | Leukemias | Completed | 2006-01-01 | 2009-06-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| CYC140 | Other | Phase PHASE1 | Solid Tumor, Adult Lymphoma | UNKNOWN | NCT05358379 |
| sapacitabine and venetoclax (Part 2 - recruiting) | Other | Phase PHASE1 | Acute Myeloid Leukemia | UNKNOWN | NCT01211457 |
| sapacitabine and decitabine (Part 1 - completed) | Other | Phase PHASE1 | Acute Myeloid Leukemia | UNKNOWN | NCT01211457 |
| Sapacitabine | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT01253460 |
| Rituximab | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT01253460 |
| Cyclophosphamide | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT01253460 |
| sapacitabine and seliciclib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00999401 |
| Decitabine | Other | Phase PHASE3 | Acute Myeloid Leukemia | COMPLETED | NCT01303796 |
| Sapacitabine | Other | Phase PHASE3 | Acute Myeloid Leukemia | COMPLETED | NCT01303796 |
| Fadraciclib | Other | Phase PHASE1 | Solid Tumor, Adult | UNKNOWN | NCT04983810 |
| Venetoclax | Other | Phase PHASE1 | Relapsed or Refractory Chronic Lymphocytic Leukemia | COMPLETED | NCT03739554 |
| CYC065 | Other | Phase PHASE1 | Relapsed or Refractory Chronic Lymphocytic Leukemia | COMPLETED | NCT03739554 |
| fadraciclib | Other | Phase PHASE1 | Leukemia | SUSPENDED | NCT05168904 |
| CYC065 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT02552953 |
| Fadraciclib | Other | Phase EARLY_PHASE1 | Healthy | COMPLETED | NCT05817890 |
| Venetoclax | Other | Phase PHASE1 | AML | COMPLETED | NCT04017546 |
| CYC065 | Other | Phase PHASE1 | AML | COMPLETED | NCT04017546 |
| CYC140 | Other | Phase PHASE1 | AML, Adult | TERMINATED | NCT03884829 |
| Placebo | Other | Phase PHASE2 | Cystic Fibrosis | TERMINATED | NCT02649751 |
| Roscovitine | Other | Phase PHASE2 | Cystic Fibrosis | TERMINATED | NCT02649751 |
| Olaparib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03641755 |
| Sapacitabine | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03641755 |
| fadraciclib | DRUG | Phase PHASE1 | Leukemia | SUSPENDED | NCT05168904 |
| Fadraciclib | DRUG | Phase EARLY_PHASE1 | Healthy | COMPLETED | NCT05817890 |
| CYC140 | DRUG | Phase PHASE1 | Solid Tumor, Adult Lymphoma | RECRUITING | NCT05358379 |
| Venetoclax | DRUG | Phase PHASE1 | AML | COMPLETED | NCT04017546 |
| Olaparib | DRUG | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03641755 |
| Placebo | DRUG | Phase PHASE2 | Cystic Fibrosis | TERMINATED | NCT02649751 |
| Roscovitine | DRUG | Phase PHASE2 | Cystic Fibrosis | TERMINATED | NCT02649751 |
| CYC065 | DRUG | Phase PHASE1 | AML | COMPLETED | NCT04017546 |
| Decitabine | DRUG | Phase PHASE3 | Acute Myeloid Leukemia | COMPLETED | NCT01303796 |
| Rituximab | DRUG | Phase PHASE2 | Leukemia | TERMINATED | NCT01253460 |
| Cyclophosphamide | DRUG | Phase PHASE2 | Leukemia | TERMINATED | NCT01253460 |
| placebo | DRUG | Phase PHASE2 | Non-small Cell Lung Cancer | TERMINATED | NCT00372073 |
| seliciclib | DRUG | Phase PHASE2 | Non-small Cell Lung Cancer | TERMINATED | NCT00372073 |
| sapacitabine and venetoclax (Part 2 - recruiting) | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | UNKNOWN | NCT01211457 |
| sapacitabine and decitabine (Part 1 - completed) | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | UNKNOWN | NCT01211457 |
| sapacitabine and seliciclib | DRUG | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00999401 |
| Sapacitabine, Arm I | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT00590187 |
| Sapacitabine, Arm H | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT00590187 |
| Sapacitabine, Arm G | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT00590187 |
| sapacitabine, Arm F | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT00590187 |
| sapacitabine, Arm E | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT00590187 |
| Sapacitabine, Arm D | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT00590187 |
| Sapacitabine, Arm C | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT00590187 |
| Sapacitabine, Arm B | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT00590187 |
| Sapacitabine, Arm A | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT00590187 |
| CYC116 | DRUG | Phase PHASE1 | Solid Tumors | TERMINATED | NCT00560716 |
| Sapacitabine | DRUG | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03641755 |
| sapacitabine | DRUG | Phase PHASE2 | Non-small Cell Lung Cancer | TERMINATED | NCT00885963 |